Inhaler technique and training in people with chronic obstructive pulmonary disease and asthma

Expert Review of Respiratory Medicine

Volumn 6, Issue 1, 2012, Pages 91-103

  Capstick, Toby G D ^a   Clifton, Ian J ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Asthma; COPD; Dry powder inhaler; Inhaler technique; Metered dose inhaler

Indexed keywords

ACCUHALER; AEROLIZER; ANTIASTHMATIC AGENT; AUTOHALER; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CLICKHALER; CORTICOSTEROID; EASI BREATHE; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; FORMOTEROL FUMARATE; HANDIHALER; PLACEBO; TIOTROPIUM BROMIDE; TURBOHALER; UNCLASSIFIED DRUG; VOLUMATIC;

AEROSOL; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; HUMAN; INHALER; MEDICAL EDUCATION; PATIENT CARE; PRESCRIPTION; RESPIRATORY AIRFLOW; REVIEW;

EID: 84856428982     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.11.89     Document Type: Review

References (63)

1. British Thoracic Society. British Guideline on the management of asthma. Thorax 63(Suppl. 4), iv1-iv121 (2008).
2. Lavorini F, Magnan A, Dubus JC et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir. Med. 102(4), 593-604 (2008).
3. Crompton GK, Barnes PJ, Broeders M et al. The need to improve inhalation technique in Europe: A report from the Aerosol Drug Management Improvement Team. Respir. Med. 100(9), 1479-1494 (2006). (Pubitemid 44109117)
4. Broeders ME, Vincken W, Corbetta L. The ADMIT series - Issues in Inhalation Therapy. 7. Ways to improve pharmacological management of COPD: The importance of inhaler choice and inhalation technique. Prim. Care Respir. J. 20(3), 338-343 (2011).
5. Horne R, Weinman J. Self-regulation and self-management in asthma: Exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol. Health 17, 7-32 (2002).
6. Horne R, Weinman J. Patient's beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J. Psychosom. Res. 47(6), 555-567 (2008).
7. Menckeberg TT, Bouvy ML, Bracke M et al. Beliefs about medicines predict refill adherence to inhaled corticosteroids. J. Psychosom. Res. 64(1), 47-54 (2008). (Pubitemid 350297308)
8. Cochrane GM, Horne R, Chanez P. Compliance in asthma. Respir. Med. 93(11), 763-769 (1999).
9. Horne R. Compliance, adherence, and concordance: Implications for asthma treatment. Chest 130(1 Suppl.), 65S-72S (2006). (Pubitemid 44107237)
10. Newman SP. Aerosol deposition considerations in inhalation therapy. Chest 88(Suppl. 2), 152S-160S (1985). (Pubitemid 16246728)
11. Everard ML. Guidelines for devices and choices. J. Aerosol Med. 14(Suppl. 1), S59-S64 (2001). (Pubitemid 32172854)
12. Nimmo CJ, Chen DN, Martinusen SM, Ustad TL, Ostrow DN. Assessment of patient acceptance and inhalation technique of a pressurized aerosol inhaler and two breath-actuated devices. Ann. Pharmacother. 27(7-8), 922-927 (1993). (Pubitemid 23225686)
13. Crompton GK. Problems patients have using pressurized aerosol inhalers. Eur. J. Respir. Dis. Suppl. 119, 101-104 (1982). (Pubitemid 12060363)
14. Hesselink AE, Penninx BW, Wijnhoven HA, Kriegsman DM, van Eijk JT. Determinants of an incorrect inhalation technique in patients with asthma or COPD. Scand. J. Prim. Health Care 19(4), 255-260 (2001). (Pubitemid 34032753)
15. Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: Assessment of use and patient preference of seven inhalation devices. EDICI. Respir. Med. 94(5), 496-500 (2000). (Pubitemid 30353008)
16. Ho SF, OMahony MS, Steward JA, Breay P, Burr ML. Inhaler technique in older people in the community. Age Ageing 33(2), 185-188 (2004). (Pubitemid 38313119)
17. Lavorini F, Corrigan CJ, Barnes PJ et al. Retail sales of inhalation devices in European countries: So much for a global policy. Respir. Med. 105(7), 1099-1103 (2011).
18. Allen SC, Prior A. What determines whether an elderly patient can use a metered dose inhaler correctly? Br. J. Dis. Chest 80(1), 45-49 (1986). (Pubitemid 16084253)
19. Chapman KR, Love L, Brubaker H. A comparison of breath-actuated and conventional metered-dose inhaler inhalation techniques in elderly subjects. Chest 104(5), 1332-1337 (1993). (Pubitemid 23327840)
20. Al-Showair RA, Tarsin WY, Assi KH, Pearson SB, Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir. Med. 101(11), 2395-2401 (2007). (Pubitemid 47471395)
21. Al-Showair RA, Pearson SB, Chrystyn H. The potential of a 2Tone Trainer to help patients use their metered-dose inhalers. Chest 131(6), 1776-1782 (2007). (Pubitemid 46981633)
22. Newman SP. Spacer devices for metered dose inhalers. Clin. Pharmacokinet. 43(6), 349-360 (2004). (Pubitemid 38594710)
23. Bloomfield P, Crompton GK, Winsey NJ. A tube spacer to improve inhalation of drugs from pressurised aerosols. Br. Med. J. 2(6203), 1479 (1979). (Pubitemid 10162319)
24. Brown PH, Blundell G, Greening AP, Crompton GK. Do large volume spacer devices reduce the systemic effects of high dose inhaled corticosteroids? Thorax 45(10), 736-739 (1990). (Pubitemid 20351899)
25. Fireman P, Prenner BM, Vincken W, Demedts M, Mol SJ, Cohen RM. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol. Ann. Allergy Asthma Immunol. 86(5), 557-565 (2001). (Pubitemid 32487856)
26. Gross G, Thompson PJ, Chervinsky P, Vanden Burgt J. Hydrofluoroalkane- 134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma. Chest 115(2), 343-351 (1999). (Pubitemid 29083039)
27. Papi A, Paggiaro P, Nicolini G, Vignola AM, Fabbri LM. Beclomethasone/ formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 62(10), 1182-1188 (2007). (Pubitemid 47374029)
28. Papi A, Paggiaro PL, Nicolini G, Vignola AM, Fabbri LM. Beclomethasone/ formoterol versus budesonide/formoterol combination therapy in asthma. Eur. Respir. J. 29(4), 682-689 (2007). (Pubitemid 46554617)
29. Fabbri LM, Nicolini G, Olivieri D, Papi A. Inhaled beclometasone dipropionate/ formoterol extra-fine fixed combination in the treatment of asthma: Evidence and future perspectives. Expert Opin. Pharmacother. 9(3), 479-490 (2008). (Pubitemid 351291792)
30. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am. J. Respir. Crit. Care Med. 172(12), 1497-1504 (2005). (Pubitemid 43076536)
31. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. J. Aerosol Med. 18(4), 379-385 (2005). (Pubitemid 43038404)
32. Gabrio BJ, Stein SW, Velasquez DJ. A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. Int. J. Pharm. 186(1), 3-12 (1999). (Pubitemid 29397518)
33. Newman SP, Weisz AW, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 46(10), 712-716 (1991).
34. Dalby R, Spallek M, Voshaar T. A review of the development of Respimat Soft Mist Inhaler. Int. J. Pharm. 283(1-2), 1-9 (2004). (Pubitemid 39200921)
35. Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis of randomised controlled trials. BMJ 342, d3215 (2011).
36. Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 359(15), 1543-1554 (2008).
37. Chrystyn H, Price D. Not all asthma inhalers are the same: Factors to consider when prescribing an inhaler. Prim. Care Respir. J. 18(4), 243-249 (2009).
38. Haughney J, Price D, Barnes NC, Virchow JC, Roche N, Chrystyn H. Choosing inhaler devices for people with asthma: Current knowledge and outstanding research needs. Respir. Med. 104(9), 1237-1245 (2010).
39. Clarke SW, Pavia D, Newman SP. Influence of different inhalation modes on the efficacy of pressurized aerosol bronchodilators. Eur. J. Respir. Dis. Suppl. 119, 79-88 (1982).
40. Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch. Dis. Child. 65(3), 308-310 (1990). (Pubitemid 20108901)
41. Newman S, Steed K, Hooper G, Kallen A, Borgstrom L. Comparison of gamma scintigraphy and a pharmacokinetic technique for assessing pulmonary deposition of terbutaline sulphate delivered by pressurized metered dose inhaler. Pharm. Res. 12(2), 231-236 (1995).
42. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metereddose inhaler compared with CFCbeclomethasone. Eur. Respir. J. 12(6), 1346-1353 (1998). (Pubitemid 29011427)
43. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone : A cross-over study in healthy volunteers. Chest 122(2), 510-516 (2002). (Pubitemid 35002128)
44. De Backer W, Devolder A, Poli G et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J. Aerosol Med. Pulm. Drug Deliv. 23(3), 137-148 (2010).
45. Hamid Q, Song Y, Kotsimbos TC et al. Inflammation of small airways in asthma. J. Allergy Clin. Immunol. 100(1), 44-51 (1997). (Pubitemid 27328530)
46. Leach C, Colice GL, Luskin A. Particle size of inhaled corticosteroids: Does it matter? J. Allergy Clin. Immunol. 124(6 Suppl.), S88-S93 (2009).
47. Vanden Burgt JA, Busse WW, Martin RJ, Szefler SJ, Donnell D. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma. J. Allergy Clin. Immunol. 106(6), 1209-1226 (2000).
48. Bell J. Why optimise inhaler technique in asthma and COPD? Br. J. Prim. Care Nurs. 2, 37-39 (2008).
49. Chrystyn H. Is inhalation rate important for a dry powder inhaler? Using the In-Check Dial to identify these rates. Respir. Med. 97(2), 181-187 (2003). (Pubitemid 36285000)
50. Borgstrom L, Bondesson E, Moren F, Trofast E, Newman SP. Lung deposition of budesonide inhaled via Turbuhaler: A comparison with terbutaline sulphate in normal subjects. Eur. Respir. J. 7(1), 69-73 (1994). (Pubitemid 24075127)
51. Palander A, Mattila T, Karhu M, Muttonen E. In vitro comparison of three salbutamol containing multidose dry powder inhalers: Buventol Easyhaler®, Inspiryl Turbuhaler® and Ventoline Diskus®. Clin. Drug Investig. 20(1), 25-33 (2000). (Pubitemid 30468209)
52. Newman SP, Pavia D, Garland N, Clarke SW. Effects of various inhalation modes on the deposition of radioactive pressurized aerosols. Eur. J. Respir. Dis. Suppl. 119, 57-65 (1982). (Pubitemid 12060356)
53. Voshaar T, App EM, Berdel D et al. [Recommendations for the choice of inhalatory systems for drug prescription]. Pneumologie 55(12), 579-586 (2001). (Pubitemid 34043044)
54. Nsour WM, Alldred A, Corrado J, Chrystyn H. Measurement of peak inhalation rates with an in-check meter to identify an elderly patient's ability to use a turbuhaler. Respir. Med. 95(12), 965-968 (2001). (Pubitemid 34013544)
55. Dolovich MB, Ahrens RC, Hess DR et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/ American College of Asthma, Allergy, and Immunology. Chest 127(1), 335-371 (2005). (Pubitemid 41724594)
56. Anderson P. Patient preferences for and satisfaction with inhaler devices. Eur. Respir. Rev. 14(96), 109-116 (2005). (Pubitemid 43028768)
57. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur. Respir. J. 19(2), 246-251 (2002). (Pubitemid 34162824)
58. Burton AJ. Asthma inhalation devices: What do we know? Br. Med. J. 288(6431), 1650-1651 (1984). (Pubitemid 14083920)
59. Interiano B, Guntupalli KK. Metered-dose inhalers. Do health care providers know what to teach? Arch. Intern. Med. 153(1), 81-85 (1993). (Pubitemid 23043372)
60. Hanania NA, Wittman R, Kesten S, Chapman KR. Medical personel's knowledge of and ability to use inhaling devices. Metered-dose inhalers, spacing chambers, and breath-actuated dry powder inhalers. Chest 105(1), 111-116 (1994). (Pubitemid 24029087)
61. Basheti I, Reddel HK, Armour CL, Bosnic-Anticevich SZ. Pharmacists' understanding of patient education on metered-dose inhaler technique. Ann. Pharmacother. 34(11), 1249-1256 (2007).
62. Assi K, Chrystyn H. The different resistance of dry powder inhalers (DPIs). Am. J. Respir. Crit. Care Med. 163(5), A443 (2001).
63. Chodosh S, Flanders JS, Kesten S, Serby CW, Hochrainer D, Witek TJ Jr. Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J. Aerosol Med. 14(3), 309-315 (2001). (Pubitemid 32802033)